These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 18753974

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens.
    Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, Chhieng DC.
    Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055
    [Abstract] [Full Text] [Related]

  • 3. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
    Bhargava R, Beriwal S, Dabbs DJ.
    Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
    [Abstract] [Full Text] [Related]

  • 4. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A, Fanger G, Khan A, Rock KL, Xu B.
    Cancer; 2004 Dec 25; 102(6):368-72. PubMed ID: 15558786
    [Abstract] [Full Text] [Related]

  • 5. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
    Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R.
    Hum Pathol; 2008 May 25; 39(5):666-71. PubMed ID: 18339419
    [Abstract] [Full Text] [Related]

  • 6. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
    Chia SY, Thike AA, Cheok PY, Tan PH.
    Breast; 2010 Oct 25; 19(5):355-9. PubMed ID: 20347310
    [Abstract] [Full Text] [Related]

  • 7. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
    Chivukula M, Dabbs DJ, O'Connor S, Bhargava R.
    Int J Gynecol Pathol; 2009 Nov 25; 28(6):570-8. PubMed ID: 19851209
    [Abstract] [Full Text] [Related]

  • 8. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW, Papadimos DJ, Walsh MD.
    Cancer Cytopathol; 2014 Apr 25; 122(4):307-12. PubMed ID: 24421220
    [Abstract] [Full Text] [Related]

  • 9. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
    Zhang Y, Garcia-Buitrago MT, Koru-Sengul T, Schuman S, Ganjei-Azar P.
    Int J Gynecol Pathol; 2013 Sep 25; 32(5):476-81. PubMed ID: 23896709
    [Abstract] [Full Text] [Related]

  • 10. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
    Cao D, Ji H, Ronnett BM.
    Int J Gynecol Pathol; 2005 Jan 25; 24(1):67-72. PubMed ID: 15626919
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [Abstract] [Full Text] [Related]

  • 13. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
    Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG.
    Ann Diagn Pathol; 2003 Apr 01; 7(2):112-9. PubMed ID: 12715337
    [Abstract] [Full Text] [Related]

  • 14. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W, Michael CW.
    Diagn Cytopathol; 2007 Jun 01; 35(6):370-5. PubMed ID: 17497661
    [Abstract] [Full Text] [Related]

  • 15. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
    Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu-Rustum N, Norton L, Tan LK.
    Am J Surg Pathol; 2005 Nov 01; 29(11):1482-9. PubMed ID: 16224215
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.
    Gynecol Oncol; 2007 Jun 01; 105(3):578-85. PubMed ID: 17343903
    [Abstract] [Full Text] [Related]

  • 17. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM, Mentrikoski MJ, Wick MR.
    Ann Diagn Pathol; 2015 Feb 01; 19(1):6-9. PubMed ID: 25544392
    [Abstract] [Full Text] [Related]

  • 18. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
    Raju UB, Lee MW, Zarbo RJ, Crissman JD.
    Mod Pathol; 1989 Nov 01; 2(6):569-76. PubMed ID: 2479944
    [Abstract] [Full Text] [Related]

  • 19. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG.
    Mod Pathol; 2003 Mar 01; 16(3):192-7. PubMed ID: 12640097
    [Abstract] [Full Text] [Related]

  • 20. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH, Shaaban HM.
    Turk Patoloji Derg; 2018 Mar 01; 34(2):143-149. PubMed ID: 29235613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.